We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Depakote ER in Borderline Personality Disorder

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00222482
First Posted: September 22, 2005
Last Update Posted: August 9, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Abbott
Schulz, S. Charles, M.D.
Information provided by:
University of Minnesota - Clinical and Translational Science Institute
  Purpose
This study examines the effect of Depakote ER versus placebo in a randomized trial of borderline personality disorder. Patients all participate in DBT therapy and those who are not responsive are assigned to either Depakote ER or placebo for up to 12 weeks. Borderline Personality Symtoms are measured and side-effects are assessed.

Condition Intervention
Borderline Personality Disorder Drug: Depakote ER

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double-Blind and Placebo Controlled Assessment of Depakote ER in Borderline Personality Disorder

Resource links provided by NLM:


Further study details as provided by University of Minnesota - Clinical and Translational Science Institute:

Primary Outcome Measures:
  • Symptom Checklist 90

Secondary Outcome Measures:
  • Barratt Impulsivity Scale

Estimated Enrollment: 15
Study Start Date: March 2003
Study Completion Date: September 2005
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:Male or female patients with the diagnosis of borderline personality disorder between the ages of 21 adn 55 years old. Must be in good physical health -

Exclusion Criteria:Major psychiatric illness on Axis I - schizophrenia or bipolar disorder. May not have current MDD. May not be dependent on illicit substances or alcohol.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00222482


Sponsors and Collaborators
University of Minnesota - Clinical and Translational Science Institute
Abbott
Schulz, S. Charles, M.D.
Investigators
Principal Investigator: Sellamnn C Schulz, M.D. Department of Psychiatry, University of Minnesota Medical School
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00222482     History of Changes
Other Study ID Numbers: 0306M49703
M009946
First Submitted: September 14, 2005
First Posted: September 22, 2005
Last Update Posted: August 9, 2007
Last Verified: August 2007

Keywords provided by University of Minnesota - Clinical and Translational Science Institute:
Borderline Personality Disorder

Additional relevant MeSH terms:
Disease
Personality Disorders
Borderline Personality Disorder
Pathologic Processes
Mental Disorders
Valproic Acid
Anticonvulsants
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
GABA Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs